ZYME NASDAQ
Credit Risk of going bust: lower than 54% of companies Debt: 11.7% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.39 (down 99%), Zymeworks Inc. would be worth roughly what it owes.
Total debt $268.6M against a stock market value of $2.04B.
Distance to default 5.50 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $129.6M (short-term plus half of long-term), stock volatility 52.7%; Altman Z'' -7.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Middletown, DE 19709
US
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Schayowitz Adam | M-Exempt | 37,037 | — | 2026-10-09 |
| Schayowitz Adam | S-Sale | 13,832 | $25.85 | 2026-10-09 |
| Schayowitz Adam | M-Exempt | 37,037 | — | 2026-10-09 |
| Hollywood Mark | A-Award | 939 | $22.22 | 2026-07-06 |
| Schneider Paul R | A-Award | 178,000 | $24.57 | 2026-05-13 |